Matthews International Capital Management LLC boosted its holdings in shares of China Biologic Products, Inc. (NASDAQ:CBPO) by 10.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 31,100 shares of the biopharmaceutical company’s stock after acquiring an additional 2,900 shares during the quarter. Matthews International Capital Management LLC owned approximately 0.11% of China Biologic Products worth $3,517,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC raised its position in China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after acquiring an additional 44 shares in the last quarter. BlackRock Inc. raised its position in China Biologic Products by 694.1% during the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after acquiring an additional 1,318,183 shares in the last quarter. Goldman Sachs Group Inc. raised its position in China Biologic Products by 9.5% during the first quarter. Goldman Sachs Group Inc. now owns 58,559 shares of the biopharmaceutical company’s stock valued at $5,863,000 after acquiring an additional 5,091 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in China Biologic Products by 9.3% during the first quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock valued at $19,848,000 after acquiring an additional 16,933 shares in the last quarter. Finally, Bank of America Corp DE raised its position in China Biologic Products by 67.3% during the first quarter. Bank of America Corp DE now owns 56,118 shares of the biopharmaceutical company’s stock valued at $5,619,000 after acquiring an additional 22,583 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on CBPO shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $140.00 price objective on shares of China Biologic Products in a research report on Monday, June 12th. BidaskClub lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) started coverage on shares of China Biologic Products in a research report on Tuesday, May 30th. They set a “neutral” rating on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $132.00.

Shares of China Biologic Products, Inc. (CBPO) traded down 5.30% during trading on Friday, reaching $90.81. 849,154 shares of the company traded hands. China Biologic Products, Inc. has a 12 month low of $88.25 and a 12 month high of $126.47. The stock has a market cap of $2.47 billion, a P/E ratio of 23.64 and a beta of 1.75. The stock’s 50 day moving average price is $93.66 and its 200-day moving average price is $104.09.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same quarter in the prior year, the firm posted $1.26 EPS. The business’s revenue was down 2.3% on a year-over-year basis. On average, equities research analysts expect that China Biologic Products, Inc. will post $4.96 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Matthews International Capital Management LLC Acquires 2,900 Shares of China Biologic Products, Inc. (CBPO)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/matthews-international-capital-management-llc-acquires-2900-shares-of-china-biologic-products-inc-cbpo/1566554.html.

About China Biologic Products

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.